Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
This article was originally published in The Pink Sheet Daily
Executive Summary
The rheumatoid arthritis agent is expected to be available by the end of February.
You may also be interested in...
Orencia Extension Data Show Two-Year Progression Benefits In RA Patients
Bristol-Myers Squibb says abatacept sustains inhibition of radiographic progression over two years in methotrexate-inadequate responders.
Orencia Extension Data Show Two-Year Progression Benefits In RA Patients
Bristol-Myers Squibb says abatacept sustains inhibition of radiographic progression over two years in methotrexate-inadequate responders.
Repligen Seeks Preliminary Injunction Against Bristol’s RA Therapy Orencia
Repligen says Bristol’s abatacept infringes Repligen’s patent for method of treating rheumatoid arthritis.